Persist AI, a Woodland, CA-based. Developed long-acting, extended-release formulation with active ingredient release rates designed to accelerate pre-clinical development time. The company uses machine learning and artificial intelligence-driven automation technologies, enabling drug manufacturers to speed up drug formulation and optimize drug loading, morphology, and distribution.
Persist AI was funded $4 million led by 2048 Ventures with participation from Innospark Ventures, Fellows Fund, YCombinator, Pioneer Fund, and other strategic angel investors in a recent funding round to propel drug formulation process advancement.
Persist AI, known for its cutting-edge artificial intelligence technologies, is dedicated to revolutionizing the drug development landscape. By harnessing the power of machine learning and predictive analytics, the company aims to expedite the formulation of new pharmaceutical compounds, ultimately enhancing the efficiency and efficacy of drug discovery.
Traditional drug formulation methods often involve trial and error, which can be time-consuming and costly. Persist AI’s platform seeks to mitigate these challenges by employing sophisticated algorithms to predict molecular interactions, identify potential side effects, and suggest optimal compound compositions. This accelerates the drug development timeline and reduces the risk of adverse reactions during clinical trials.
Karthik Raman, co-founder, and CEO of Persist AI expressed their enthusiasm about the recent funding round: They are thrilled to have the support of such esteemed investors who share their vision of transforming the pharmaceutical industry. This capital injection will enable them to scale our research efforts, refine our algorithms, and collaborate with pharmaceutical partners to bring safer and more effective drugs to market quickly.
Persist AI’s technology has already shown promising results in early-stage testing, demonstrating its ability to predict molecular behaviors accurately. With the additional funding, the company plans to expand its team of AI researchers and forge strategic partnerships with leading pharmaceutical companies to validate further and refine its platform.
The pharmaceutical industry has been increasingly adopting AI and machine learning solutions to streamline various drug discovery and development aspects. Persist AI’s innovative approach places it in a strategic position to make significant contributions to the field, potentially ushering in a new era of accelerated and more precise drug formulation.
As Persist AI continues to make strides in its research and collaborations, the company’s progress could potentially lead to groundbreaking advancements in pharmaceutical sciences, ultimately benefiting patients worldwide by bringing novel treatments to market faster and more efficiently.
By: K. Tagura
Author statement:
Who we are: Funded.com is a platform that is A+ BBB accredited over 10+ years. Access our network of Angel Investors, Venture Capital or Lenders. Let us professionally write your Business Plan.
Rss Feed
